2025
Biomarkers in Autosomal Dominant Tubulointerstitial Kidney Disease
Li M, Jiang L, Liu Z, You R, Li Y, Xiang C, Yang L, Zhang H, Zhou X. Biomarkers in Autosomal Dominant Tubulointerstitial Kidney Disease. Integrative Medicine In Nephrology And Andrology 2025, 12 DOI: 10.1097/imna-d-24-00050.Peer-Reviewed Original ResearchAutosomal dominant tubulointerstitial kidney diseaseChronic kidney diseaseTubulointerstitial kidney diseaseKidney diseaseProgressive chronic kidney diseaseDelay kidney failureVariable clinical featuresUric acid levelsControl blood pressureRenal interstitial fibrosisImprove patient outcomesPotential therapeutic targetClinical featuresClinical manifestationsTreatment optionsInterstitial fibrosisInsidious onsetClinical indicationsDisease progressionTubular proteinuriaEarly diagnosisBlood pressurePathological featuresAdvanced stageKidney failureReal-world outcomes with T-VEC in patients with anti-PD-1 resistant in-transit disease from melanoma and Merkel cell carcinoma
Su D, McNamara M, Kaszycki M, Frey A, Ishizuka J, Costa P, Tran T, Kluger H, Clune J, Weiss S, Olino K. Real-world outcomes with T-VEC in patients with anti-PD-1 resistant in-transit disease from melanoma and Merkel cell carcinoma. Surgical Oncology Insight 2025, 2: 100120. DOI: 10.1016/j.soi.2024.100120.Peer-Reviewed Original ResearchMerkel cell carcinomaMerkel cell carcinoma casesT-VECCell carcinomaMedian numberAnti-PD-1 blockadeStage IIIB-IV melanomaAdvanced Merkel cell carcinomaIn-transit melanomaIn-transit diseaseICI therapyTalimogene laherparepvecAdvanced melanomaCancer immunotherapyMetastatic sitesPartial responseIn-transitRegional metastasesMedian ageGrade 3Adverse eventsTreatment cyclesDisease progressionMelanomaPatientsCardiac treatment for Duchenne muscular dystrophy: consensus recommendations from the ACTION muscular dystrophy committee.
Esteso P, Auerbach S, Bansal N, Harris R, Soslow J, Birnbaum B, Conway J, Cripe L, Nandi D, Hayes E, Gambetta K, Hall E, Hsu D, Kaufman B, Rosenthal D, Kirmani S, Ploutz M, Lal A, Peng D, Villa C, Shugh S, Wittlieb-Weber C, Shih R. Cardiac treatment for Duchenne muscular dystrophy: consensus recommendations from the ACTION muscular dystrophy committee. Cardiology In The Young 2025, 1-6. PMID: 40012319, DOI: 10.1017/s1047951125000587.Peer-Reviewed Original ResearchDuchenne muscular dystrophyCardiac medicationsMuscular dystrophyCardiac careAdvanced Cardiac Therapies Improving Outcomes NetworkManagement of Duchenne muscular dystrophyImprove cardiac outcomesLoss of dystrophinAmerican College of CardiologyOptimal therapeutic efficacyExpert opinion statementsAmerican Heart AssociationCardiac outcomesImprove cardiac prognosisCardiomyopathy progressionTherapeutic efficacyCardiac prognosisHeart AssociationDisease progressionCardiac treatmentConsensus recommendationsOutcomes NetworkAmerican CollegeDystrophyCardiomyopathyMetabolic Phenotype of Stage 1 and Stage 2 Type 1 Diabetes Using Modeling of β Cell Function
Galderisi A, Bonet J, Ismail H, Moran A, Fiorina P, Bosi E, Petrelli A. Metabolic Phenotype of Stage 1 and Stage 2 Type 1 Diabetes Using Modeling of β Cell Function. The Journal Of Clinical Endocrinology & Metabolism 2025, dgaf086. PMID: 39992257, DOI: 10.1210/clinem/dgaf086.Peer-Reviewed Original ResearchOral glucose tolerance testMetabolic phenotypeOral minimal modelInsulin secretionResponse to disease-modifying treatmentsOdds of disease progressionPhenotype of individualsPrevention trialsPreclinical type 1 diabetesIndependent of stageMeasures of beta-cell functionStage 1Glucose tolerance testAssociated with reduced oddsBeta-cell functionMeasures of insulin secretionType 1 diabetesOGTT-derived measuresIncreased insulin clearanceT1D prevention trialsIslet autoimmunityDisease-modifying treatmentsTolerance testDisease progressionProgression predictorsImpact of Tumor Stage on Oncologic Outcomes of High-grade Bacillus Calmette-Guérin Unresponsive Non–muscle-invasive Bladder Cancer Undergoing Bladder-sparing Therapies
Annapureddy D, Taylor J, Kamat A, O'Donnell M, Howard J, Tan W, McElree I, Davaro F, Yim K, Harrington S, Dyer E, Black A, Kanabur P, Roumiguié M, Lerner S, Black P, Raman J, Preston M, Steinberg G, Huang W, Li R, Packiam V, Woldu S, Lotan Y. Impact of Tumor Stage on Oncologic Outcomes of High-grade Bacillus Calmette-Guérin Unresponsive Non–muscle-invasive Bladder Cancer Undergoing Bladder-sparing Therapies. European Urology Focus 2025 PMID: 39922753, DOI: 10.1016/j.euf.2025.01.001.Peer-Reviewed Original ResearchNon-muscle-invasive bladder cancerCarcinoma in situBCG-unresponsive NMIBCBladder-sparing therapyOncological outcomesTumor stageBladder cancer mortalityCancer mortalityAssociated with worse oncologic outcomesPresence of carcinoma in situCarcinoma in situ groupImpact of tumor stageTA groupKaplan-Meier methodPapillary diseaseT1 diseaseRadical cystectomyNo significant differenceClinical stageBladder cancerSurvival differencesRetrospective natureCis groupDisease progressionMetastasisThe sex differences in diseases progression and prognosis among persons with HIV and HBV coinfection
Yang R, Chen Q, Jiao F, Yu X, Xiong Y. The sex differences in diseases progression and prognosis among persons with HIV and HBV coinfection. Scientific Reports 2025, 15: 4018. PMID: 39893294, PMCID: PMC11787304, DOI: 10.1038/s41598-025-88530-2.Peer-Reviewed Original ResearchConceptsCD4+ T-lymphocyte countT lymphocyte countsEnd-stage-liver diseaseFIB-4 scoreHBV coinfectionFIB-4HBV DNADecline of HBV DNA levelsDisease progressionLong-term surveillance periodRisk factorsPrevalence of liver cirrhosisHBV co-infectionMultivariate logistic regression analysisHBV DNA levelsProgression of liver diseaseIndependent risk factorLiver disease progressionLiver fibrosis levelsAll-cause mortalityMultivariate logistic regressionLogistic regression analysisMale groupSex differencesFemale groupRecent advances in the management of pediatric cholestatic liver diseases
Mysore K, Cheng K, Suri L, Fawaz R, Mavis A, Kogan‐Liberman D, Mohammad S, Taylor S. Recent advances in the management of pediatric cholestatic liver diseases. Journal Of Pediatric Gastroenterology And Nutrition 2025 PMID: 39840645, DOI: 10.1002/jpn3.12462.Peer-Reviewed Original ResearchPediatric cholestatic liver diseasesCholestatic liver diseaseIleal bile acid transporterAlagille syndromeSlow disease progressionLiver diseaseBile acid transporterMedical therapyIleal bile acid transporter inhibitorClinical trialsDisease progressionProgressive familial intrahepatic cholestasisFamilial intrahepatic cholestasisPediatric liver transplantationBile acid toxicityCurative medical therapyAcid transportImprove patient qualityIntrahepatic cholestasisBiliary atresiaSurgical managementRare conditionLiver transplantationNutritional supportUnderlying etiologyManaging risk factors and early intervention for chronic kidney disease
Kalyesubula R, Luyckx V. Managing risk factors and early intervention for chronic kidney disease. Nature Reviews Nephrology 2025, 21: 149-150. PMID: 39814983, DOI: 10.1038/s41581-025-00930-9.Peer-Reviewed Original ResearchManagement of risk factorsImplementation of interventionsBurden of kidney diseaseGlobal burden of kidney diseaseRisk factorsManaging risk factorsQuality careKidney diseaseGlobal burdenEquitable accessPrevent disease progressionEarly interventionChronic kidney diseaseInterventionDisease progressionEarly diagnosis
2024
Second‐Line Treatment for Patients With Primary Biliary Cholangitis: A Systematic Review With Network Meta‐Analysis
Giannini E, Pasta A, Calabrese F, Labanca S, Marenco S, Pieri G, Torres M, Strazzabosco M. Second‐Line Treatment for Patients With Primary Biliary Cholangitis: A Systematic Review With Network Meta‐Analysis. Liver International 2024, 45: e16222. PMID: 39720853, PMCID: PMC11669080, DOI: 10.1111/liv.16222.Peer-Reviewed Original ResearchConceptsPrimary biliary cholangitisSecond-line treatmentNetwork meta-analysisObeticholic acid 5Obeticholic acidBiliary cholangitisRelative riskIncomplete response to ursodeoxycholic acidPlacebo-controlled trial of patientsUrsodeoxycholic acidResponse to ursodeoxycholic acidSecond-line therapyIncreased risk of SAEsPlacebo-controlled trialIncidence of pruritusMeta-analysisTrial of patientsPrevent disease progressionRisk of SAEsCompare relative risksComparative efficacyDisease progressionIncreased riskBiochemical responsesSecondary outcomesImpact of antiparasitic therapy on cardiovascular outcomes in chronic Chagas disease. A systematic review and meta-analysis
Rassi A, Grimshaw A, Sarwal A, Sah R, Shah S, Agudelo Higuita N, Rassi F, Corbisiero M, Kyllo H, Stellern J, Kaplan S, Marcos L, Ramírez-García E, Casapia M, Hotez P, Bottazzi M, Patel S, Franco-Paredes C, Marin-Neto J, Henao-Martínez A. Impact of antiparasitic therapy on cardiovascular outcomes in chronic Chagas disease. A systematic review and meta-analysis. EClinicalMedicine 2024, 79: 102972. PMID: 39810938, PMCID: PMC11732499, DOI: 10.1016/j.eclinm.2024.102972.Peer-Reviewed Original ResearchChronic Chagas diseaseMethodological quality of studiesCardiovascular deathQuality of studiesDisease progressionQuality of evidenceVirtual Health Library databasesRisk of bias scaleCardiovascular outcomesRandom-effects modelPooled risk ratioMeta-analysis of studiesMethodological qualityWeb of Science Core CollectionAntitrypanosomal therapyRandomized controlled studyManagement of Chagas diseaseOvid MEDLINESystematic reviewInclusion criteriaMeta-analysesRisk ratioScience Core CollectionPrimary outcomeOvid EmbaseEfficacy of Subsequent Treatments After Disease Progression on CDK4/6 Inhibitors in Patients With Hormone Receptor-Positive Advanced Breast Cancer.
Ravani L, Calomeni P, Vilbert M, Madeira T, Wang M, Deng D, Testa L, Colombo Bonadio R, Clifton K, Wander S, Lustberg M. Efficacy of Subsequent Treatments After Disease Progression on CDK4/6 Inhibitors in Patients With Hormone Receptor-Positive Advanced Breast Cancer. JCO Oncology Practice 2024, op2400649. PMID: 39689274, DOI: 10.1200/op-24-00649.Peer-Reviewed Original ResearchProgression-free survivalAdvanced breast cancerEndocrine therapyOverall survivalDisease progressionET monotherapyHormone receptor-positive/human epidermal growth factor receptor 2-negativeBreast cancerHormone receptor-positive advanced breast cancerAssociated with longer progression-free survivalPooled analysisHR+ HER2- advanced breast cancerCyclin-dependent kinase 4/6 inhibitorsHER2- advanced breast cancerMeta-analysis searching PubMedLonger progression-free survivalProgression-free survival benefitStandard of careIndividual patient dataPatient dataCDK4/6i therapyProlonged OSCDK4/6 inhibitorsCDK4/6iTreatment optionsIntracellular endothelial cell metabolism in vascular function and dysfunction
Citrin K, Chaube B, Fernández-Hernando C, Suárez Y. Intracellular endothelial cell metabolism in vascular function and dysfunction. Trends In Endocrinology And Metabolism 2024 PMID: 39672762, DOI: 10.1016/j.tem.2024.11.004.Peer-Reviewed Original ResearchFatty acid oxidationEndothelial cellsIntracellular metabolic pathwaysInner lining of blood vesselsVascular functionCell metabolismMetabolic pathwaysEndothelial cell metabolismLipid handlingDesign new therapiesRegulate vascular toneInfluence disease progressionAcid oxidationMetabolic signaturesVascular toneNew therapiesLining of blood vesselsDisease progressionLeukocyte adhesionMetabolic changesVascular diseaseOxidative stressBlood vesselsIncreased permeabilityWound healingConsistent frontal-limbic-occipital connections in distinguishing treatment-resistant and non-treatment-resistant schizophrenia
Zhang Y, Gao S, Liang C, Bustillo J, Kochunov P, Turner J, Calhoun V, Wu L, Fu Z, Jiang R, Zhang D, Jiang J, Wu F, Peng T, Xu X, Qi S. Consistent frontal-limbic-occipital connections in distinguishing treatment-resistant and non-treatment-resistant schizophrenia. NeuroImage Clinical 2024, 45: 103726. PMID: 39700898, PMCID: PMC11721508, DOI: 10.1016/j.nicl.2024.103726.Peer-Reviewed Original ResearchNon-treatment-resistant schizophreniaTreatment-resistant schizophreniaFunctional connectivityDiagnosis of SZHealthy controlsFrontal-parietalResting-state functional connectivityAutomated anatomical labelingDysfunctional brain connectivityBrain functional connectivityAffiliated Brain Hospital of Nanjing Medical UniversityFrontal limbBrain connectivitySchizophreniaMedication dosageTreatment resistanceNeural pathwaysNanjing Medical UniversityDisease progressionMedical UniversityClinical practiceSpecific biomarkersDiagnosisAnatomical labelingUnlocking the potential of miRNAs in detecting pulmonary tuberculosis: prospects and pitfalls
Arya R, Kumar S, Vinetz J, Kim J, Chaurasia R. Unlocking the potential of miRNAs in detecting pulmonary tuberculosis: prospects and pitfalls. Expert Reviews In Molecular Medicine 2024, 26: e32. PMID: 39639643, PMCID: PMC11629464, DOI: 10.1017/erm.2024.29.Peer-Reviewed Original ResearchConceptsDisease stageHIV co-infectionAnti-TB therapyPotential of miRNAsInfectious diseasesPulmonary TBPulmonary tuberculosisActive TBFalse-positive outcomesTB diagnosticsDisease progressionLack of specificityPrognostic signatureCo-infectionLethal infectious diseaseDeadliest infectious diseasesPoint-of-care testingTuberculosisDiagnostic biomarkersStandard protocolDiseaseBiomarkersGene expressionNon-invasiveRegulatory roleRecent advances in portable, low-field magnetic resonance imaging in cerebrovascular disease
Zabinska J, de Havenon A, Sheth K. Recent advances in portable, low-field magnetic resonance imaging in cerebrovascular disease. Current Opinion In Neurology 2024, 38: 35-39. PMID: 39624032, DOI: 10.1097/wco.0000000000001338.Peer-Reviewed Original ResearchConceptsCerebrovascular diseaseWhite matter hyperintensityHealthcare settingsHemorrhage managementAlzheimer's dementiaClinical timepointsStages of cerebrovascular diseaseHemorrhagic strokeEmergency settingWhite matter hyperintensitiesIntracerebral hemorrhage managementCardiovascular intensive careThrombolytic administrationPatient populationCerebrovascular disease progressionIntensive careMagnetic resonance imagingStrokeEndovascular reperfusionCerebrovascularCost-effectiveDisease progressionResonance imagingChronic stageCareNeuroimaging Biomarkers in Parkinson’s Disease
Holmes S, Tinaz S. Neuroimaging Biomarkers in Parkinson’s Disease. Advances In Neurobiology 2024, 40: 617-663. PMID: 39562459, DOI: 10.1007/978-3-031-69491-2_21.Peer-Reviewed Original ResearchConceptsPublic health burdenNeuroimaging biomarkersTreatment developmentRisk of developing PDParkinson's diseaseHealth burdenDiagnosis of PDMultimodal neuroimaging techniquesIdiopathic Parkinson's diseaseNon-motorDifferential diagnosis of PDNeuroimaging techniquesProdromal phaseDifferential diagnosisSymptomatic treatmentDisease progressionClinical applicationBiomarkersPhenotypic Heterogeneity in Pathogens
Sherry J, Rego E. Phenotypic Heterogeneity in Pathogens. Annual Review Of Genetics 2024, 58: 183-209. PMID: 39083846, DOI: 10.1146/annurev-genet-111523-102459.Peer-Reviewed Original ResearchPhenotypic heterogeneityGenetically identical populationSalmonella typhimurium</i>Genetic diversityPathogen diversityPathogen populationsBacterial pathogensPathogen subpopulationsGenetic heterogeneityInvading pathogensHost organismFluctuating environmentsInfectious disease progressionPathogensIdentical populationsTreatment escapeInfection outcomesHeterogeneous subpopulationsDisease progressionInfecting organismDiversityCausative linkGeneticsSubpopulationsPhenotypePrimary Biliary Cholangitis: personalizing second-line therapies.
Levy C, Bowlus C. Primary Biliary Cholangitis: personalizing second-line therapies. Hepatology 2024 PMID: 39707635, DOI: 10.1097/hep.0000000000001166.Peer-Reviewed Original ResearchPrimary biliary cholangitisSecond-line agentsUrsodeoxycholic acidInadequate response to UDCAResponse to UDCADiagnosis of primary biliary cholangitisDisease progressionTreatment of primary biliary cholangitisRisk of disease progressionLong-term clinical outcomesProgression to biliary cirrhosisCohort study of patientsPeroxisome proliferator-activated receptor agonistsSecond-line therapyOff-label therapyAnti-mitochondrial antibodiesIntralobular bile ductsSymptoms of pruritusStudy of patientsBile acid physiologyDelay disease progressionSerum alkaline phosphataseMiddle-aged womenImprove cholestasisLiver biochemistryPharmacological management of pediatric metabolic dysfunction‐associated steatotic liver disease
Jaoudeh R, Hartmann P, Olson O, Gupta O, Kumar S, Ibrahim S, Fawaz R, Aqul A, Hassan S. Pharmacological management of pediatric metabolic dysfunction‐associated steatotic liver disease. Journal Of Pediatric Gastroenterology And Nutrition 2024, 80: 14-24. PMID: 39526564, DOI: 10.1002/jpn3.12402.Peer-Reviewed Original ResearchGLP-1RABody mass indexLiver diseasePediatric patientsPediatric obesityEfficacy of GLP-1RADisease progressionGlucagon-like peptide-1 receptor agonistsSteatotic liver diseaseManagement of pediatric patientsPeptide-1 receptor agonistsClinical management of pediatric patientsAdverse liver outcomesInduce weight lossLong-term efficacyHepatic manifestation of obesityLiver enzyme levelsAlternative therapeutic strategiesHalting disease progressionManifestation of obesityNonalcoholic fatty liver diseaseChildhood obesity ratesFatty liver diseaseReceptor agonistsLiver transplantationNIMG-30. DEUTERIUM METABOLIC IMAGING (DMI) SHOWS A STRONG RELATION BETWEEN TUMOR GRADE AND GLUCOSE METABOLISM IN PRIMARY BRAIN TUMORS
Thaw-Poon S, Blondin N, Liu Y, Corbin Z, Baehring J, Omuro A, Moliterno J, Omay S, Fulbright R, de Graaf R, De Feyter H. NIMG-30. DEUTERIUM METABOLIC IMAGING (DMI) SHOWS A STRONG RELATION BETWEEN TUMOR GRADE AND GLUCOSE METABOLISM IN PRIMARY BRAIN TUMORS. Neuro-Oncology 2024, 26: viii201-viii201. PMCID: PMC11553074, DOI: 10.1093/neuonc/noae165.0795.Peer-Reviewed Original ResearchGrade 2 lesionsTumor gradeDeuterium metabolic imagingMetabolic imagingNon-enhancing tumor regionsBrain tumorsTumor-to-brain contrastTumour-specific valuesActive tumor tissueImage contrastVOI-based analysisGrade 4Evaluate disease progressionTesla MRI scannerFDG-PETGrade 3Lesion gradeTumor tissuesDisease progressionDisease stageOral administrationTumorObservational studyNormal brainContrast enhancement
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply